In portal: Breast Cancer

Study : Systemic racism may delay breast biopsy for Black and Asian people

Relevance: Medium-High

Strength of Science: Medium-High

Most relevant for: People who have had an abnormal mammogram

Black and Asian people are more likely to have to wait more than 90 days between an abnormal mammogram and a biopsy compared to white people. After accounting for other factors, the authors conclude that these disparities may be due to systemic racism. (Posted 3/8/23)

Este artículo está disponible en español.

Study : Treatment to reduce bone fractures also improves breast cancer survival in postmenopausal people

Relevance: High

Strength of Science: High

Most relevant for: People with early-stage breast cancer who are post-menopausal

A large study looked at the effects of adding the bone-protective drug denosumab (Prolia), to standard hormone therapy for the treatment of early-stage, postmenopausal, HR-positive breast cancer. The researchers found that adding denosumab to aromatase inhibitor hormonal therapy improved bone health, disease-free survival and overall survival. (Posted 2/27/23)

Este artículo está disponible en español.

Study : Increasing soy in your diet may lower your cancer risk

Relevance: Medium

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: People interested in reducing cancer risk

This study looked at a link between a diet rich in soy and cancer risk. With the addition of more recent literature, this study suggests that soy lowers the risk of cancer in the general population. (Posted 2/24/23)

Este artículo está disponible en español.

Study : Trodelvy benefits people with advanced hormone-positive metastatic breast cancer

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with ER/PR-positive, HER2-negative metastatic breast cancer

The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23)

Update: On 02/03/2023 the FDA approved Trodelvy for patients with locally advanced or metastatic  breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.

Este artículo está disponible en español.

Update : Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations

Relevance: Medium

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with a BRCA1 or PALB2 mutation undergoing prophylactic bilateral mastectomy

A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23) Este artículo está disponible en español.

Study : Male breast cancer: Patient and surgeon experiences

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

Most relevant for: Men with breast cancer

By surveying male breast cancer patients and the surgeons who treat them, researchers gained insight into the experiences of both groups, shedding light on an important issue for men with breast cancer. (Posted 12/22/22)

Este artículo está disponible en español.

Topic : Cancer disparities in American Indian and Alaska Native populations

Relevance: High

Strength of Science: High

View Related Clinical Trials

Most relevant for: Americans Indians and Alaska Natives

The American Cancer Society released a special section in their 2022 Cancer Facts & Figures report that discussed cancer disparities in American Indian and Alaska Native populations in the United States. This review highlights the special section’s main points, including disparities in cancer screening, diagnosis and survival rates in native communities, as well as factors contributing to those disparities. (Posted 12/20/22)

Este artículo está disponible en español.

Guideline : Guidelines on exercise, diet, and weight during cancer treatment

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: People currently undergoing treatment for cancer

Most professional guidelines on exercise, diet and weight management have focused on the health of the general population and cancer survivors. The American Society of Clinical Oncology (ASCO) has now published evidence-based recommendations for exercise, diet and weight specifically for people who are in active treatment for cancer. (Posted 11/29/22)  Este artículo está disponible en español.

Study : Teens and young adults respond well to learning about familial cancer risk

Relevance: Medium-High

Strength of Science: Medium-High

Most relevant for: Mothers who have had genetic testing for BRCA1 or BRCA2 whether or not they have been diagnosed with breast or ovarian cancer

Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022) Este artículo está disponible en español.

Study : Acupuncture may ease breast cancer treatment side effects

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People considering acupuncture for managing breast cancer treatment symptoms.

Acupuncture can ease some symptoms of breast cancer treatment. Multiple studies found that acupuncture is a safe and effective strategy to manage certain symptoms but also called for more rigorous research on the topic. (Posted 9/28/22) Este artículo está disponible en español.